Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
80 enrolled
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Phase 2 Recruiting
2,900 enrolled
AndroMETa-CRC
Phase 2 Recruiting
390 enrolled
A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer
Phase 2 Recruiting
63 enrolled
TORCH-iTNT
Phase 2 Recruiting
192 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Phase 2 Recruiting
164 enrolled
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
Phase 2 Recruiting
10 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Phase 2 Recruiting
144 enrolled
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
276 enrolled
SCOTI
Phase 2 Recruiting
50 enrolled
TRIUNITE-08
Phase 2 Recruiting
106 enrolled
Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)
Phase 2 Recruiting
35 enrolled
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Phase 2 Recruiting
40 enrolled
PANCREAS
Phase 2 Recruiting
84 enrolled
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Phase 2 Recruiting
50 enrolled
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
30 enrolled
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Phase 2 Recruiting
42 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Phase 2 Recruiting
27 enrolled
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Phase 2 Recruiting
36 enrolled
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
Phase 2 Recruiting
36 enrolled
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Recruiting
25 enrolled
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 Recruiting
49 enrolled
Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer
Phase 2 Recruiting
198 enrolled
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Phase 2 Recruiting
45 enrolled
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
Phase 2 Recruiting
38 enrolled
PANC
Phase 2 Recruiting
125 enrolled
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Phase 2 Recruiting
116 enrolled
CEIL
Phase 2 Recruiting
198 enrolled
TRIFLUOX-DP
Phase 2 Recruiting
73 enrolled
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Phase 2 Recruiting
60 enrolled
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Phase 2 Recruiting
20 enrolled
GRACIE
Phase 2 Recruiting
88 enrolled
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Phase 2 Recruiting
106 enrolled
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Phase 2 Recruiting
60 enrolled
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Phase 2 Recruiting
25 enrolled
Remission
Phase 2 Recruiting
30 enrolled
NeoCHIC
Phase 2 Recruiting
56 enrolled
BIG
Phase 2 Recruiting
120 enrolled
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2 Recruiting
40 enrolled
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
Phase 2 Recruiting
130 enrolled
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Phase 2 Recruiting
138 enrolled
SPARC
Phase 2 Recruiting
55 enrolled
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
26 enrolled
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
180 enrolled
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2 Recruiting
56 enrolled
OPTICAL-2
Phase 2 Recruiting
143 enrolled